Get the Stockscreener App
2.22
1.37%
0.03
After Hours:
2.26
0.04
+1.80%
Black Diamond Therapeutics Inc stock is traded at $2.22, with a volume of 811.46K.
It is up +1.37% in the last 24 hours and down -8.64% over the past month.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
See More
Previous Close:
$2.19
Open:
$2.14
24h Volume:
811.46K
Relative Volume:
0.71
Market Cap:
$125.62M
Revenue:
-
Net Income/Loss:
$-82.44M
P/E Ratio:
-0.9737
EPS:
-2.28
Net Cash Flow:
$-66.75M
1W Performance:
-13.28%
1M Performance:
-8.64%
6M Performance:
-55.42%
1Y Performance:
-16.23%
1-Day Range:
$2.09
$2.26
1-Week Range:
$2.09
$2.6591
52-Week Range:
$2.09
$7.66
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Name
Black Diamond Therapeutics Inc
Sector
Industry
Phone
617-417-5868
Address
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Compare BDTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.22 | 125.62M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-31-24 | Initiated | Raymond James | Outperform |
| Jul-14-23 | Initiated | Piper Sandler | Overweight |
| Jun-30-23 | Upgrade | Stifel | Hold → Buy |
| Jun-28-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Jun-27-23 | Upgrade | Wedbush | Neutral → Outperform |
| Mar-29-22 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-22-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Sep-30-21 | Initiated | Stifel | Hold |
| Jan-07-21 | Initiated | Wedbush | Outperform |
| Nov-24-20 | Initiated | Berenberg | Buy |
| May-04-20 | Initiated | H.C. Wainwright | Buy |
| Feb-24-20 | Initiated | Canaccord Genuity | Buy |
| Feb-24-20 | Initiated | Cowen | Outperform |
| Feb-24-20 | Initiated | JP Morgan | Overweight |
| Feb-24-20 | Initiated | Jefferies | Buy |
View All
Black Diamond Therapeutics Inc Stock (BDTX) Latest News
Charles Schwab Investment Management Inc. Boosts Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
BDTX stock touches 52-week low at $2.31 amid market challenges - Investing.com India
Analytical Overview: Black Diamond Therapeutics Inc (BDTX)’s Ratios Tell a Financial Story - The Dwinnex
Fmr LLC Makes New Investment in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
US Penny Stocks Spotlight: Information Services Group Among 3 Top Picks - Simply Wall St
Black Diamond (BDTX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Fmr LLC Decreases Stock Position in Mobileye Global Inc. (NASDAQ:MBLY) - Defense World
MFA Financial, Inc. (NYSE:MFA) Shares Sold by Fmr LLC - Defense World
BNP Paribas Financial Markets Purchases 111,027 Shares of Under Armour, Inc. (NYSE:UA) - Defense World
Fmr LLC Has $15.49 Million Stake in Schrödinger, Inc. (NASDAQ:SDGR) - Defense World
MetLife Investment Management LLC Raises Stake in Smith-Midland Co. (NASDAQ:SMID) - Defense World
BNP Paribas Financial Markets Raises Stake in RadNet, Inc. (NASDAQ:RDNT) - Defense World
Fmr LLC Increases Position in AppFolio, Inc. (NASDAQ:APPF) - Defense World
Fmr LLC Raises Stock Position in ADT Inc. (NYSE:ADT) - Defense World
Charles Schwab Investment Management Inc. Sells 309,336 Shares of Unisys Co. (NYSE:UIS) - Defense World
Point72 Asset Management L.P. Takes $3.03 Million Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
Vestal Point Capital LP Purchases 2,928,500 Shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - MarketBeat
Gene and Cell Therapies Targeting CNS Disorders Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Revenue, Statistics, Therapies, Prevalence, Companies by DelveInsight - The Globe and Mail
Gene and Cell Therapies Targeting CNS Disorders Treatment - openPR
Genesis Therapeutics presents new PI3Kα mutant inhibitors - BioWorld Online
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Decrease in Short Interest - MarketBeat
T. Rowe Price Investment Management, Inc. Expands Stake in Black Diamond Therapeutics Inc - GuruFocus.com
Vestal Point Capital, LP Increases Stake in Black Diamond Therap - GuruFocus.com
What is HC Wainwright's Estimate for BDTX FY2024 Earnings? - MarketBeat
Wedbush Has Optimistic View of BDTX FY2024 Earnings - MarketBeat
Black Diamond Therapeutics (NASDAQ:BDTX) Receives "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Black Diamond Therapeutics Reports Promising Q3 2024 Results - TipRanks
Black Diamond: Q3 Earnings Snapshot - San Francisco Chronicle
BDTXBlack Diamond Therapeutics, Inc. Latest Stock News & Market Updates - StockTitan
Vanda Pharmaceuticals Leads The Pack Of 3 US Penny Stocks - Simply Wall St
Black Diamond's BDTX-1535 Shows 42% Response Rate in Lung Cancer Trial, Reports Q3 Results | BDTX Stock News - StockTitan
Black Diamond Group Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Black Diamond Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Sees Large Growth in Short Interest - Defense World
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Short Interest Up 5.9% in October - MarketBeat
Foundations Investment Advisors LLC Has $445,000 Stake in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) looking to reclaim success with recent performance - SETE News
Investing in Black Diamond Therapeutics Inc (BDTX) Is Getting More Attractive - Knox Daily
Results from Black Diamond Therapeutics Inc (BDTX) show potential - US Post News
Market Update: Black Diamond Therapeutics Inc (BDTX) Sees Negative Movement, Closing at 3.33 - The Dwinnex
Dimensional Fund Advisors LP Has $932,000 Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Black Diamond Therapeutics Inc [BDTX] Records 200-Day SMA of $4.87 - Knox Daily
FY2024 EPS Estimates for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Increased by Analyst - MarketBeat
Analysts’ Recent Ratings Changes for Black Diamond Therapeutics (BDTX) - Defense World
Black Diamond Therapeutics Inc (BDTX) is looking forward to a strong quarter - SETE News
Cuts for Black Diamond as runway's end nears - The Pharma Letter
Q3 2024 Earnings Estimate for Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Issued By Wedbush - MarketBeat
Layoffs at local cancer drug developer; Flagship names new managing partner - The Business Journals
Black Diamond Therapeutics (NASDAQ:BDTX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Black Diamond Therapeutics Inc Stock (BDTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):